PFBT
SPRY icon

Parkside Financial Bank & Trust’s ARS Pharmaceuticals SPRY Stock Holding History

Parkside Financial Bank & Trust’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$641 Hold
80
– – ﹤0.01% 2551
2026
Q1 		$643 Buy
+80
New +$767 ﹤0.01% 2491
2025
Q4 		– Sell
-45
Closed -$453 – 2794
2025
Q3 		$453 Hold
45
– – ﹤0.01% 2595
2025
Q2 		$786 Hold
45
– – ﹤0.01% 2338
2025
Q1 		$567 Buy
+45
New +$541 ﹤0.01% 2308

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Parkside Financial Bank & Trust's SPRY Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 80 shares worth $641. The position accounts for ﹤0.01% of the portfolio, ranked #2551.

Parkside Financial Bank & Trust first reported a position in SPRY in Q1 2025 and has held it in 5 quarters since. The position peaked at $786 in Q2 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Parkside Financial Bank & Trust held 80 shares of ARS Pharmaceuticals worth $641 as of Q2 2026.
  • Parkside Financial Bank & Trust left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2551 holding.
  • Parkside Financial Bank & Trust first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Parkside Financial Bank & Trust's ARS Pharmaceuticals position peaked at $786 in Q2 2025.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.